scholarly journals Impact of Alzheimer’s disease on the family caregiver’s long-term quality of life: results from an ALSOVA follow-up study

2015 ◽  
Vol 25 (3) ◽  
pp. 687-697 ◽  
Author(s):  
Tarja H. Välimäki ◽  
Janne A. Martikainen ◽  
Kristiina Hongisto ◽  
Saku Väätäinen ◽  
Harri Sintonen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Follow Up Study ◽  
The Family

scholarly journals Effects of anosognosia and neuropsychiatric symptoms on the quality of life of patients with Alzheimer's disease: a 24-month follow-up study

2015 ◽  
Vol 31 (2) ◽  
pp. 109-119 ◽  
Author(s):  
Josep L. Conde-Sala ◽  
Oriol Turró-Garriga ◽  
Sara Piñán-Hernández ◽  
Cristina Portellano-Ortiz ◽  
Vanesa Viñas-Diez ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychiatric Symptoms ◽  
Follow Up Study

scholarly journals HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii352-iii352
Author(s):  
Hung Tran ◽  
Robert Cooper
Keyword(s):  
Growth Velocity ◽  
Direct Result ◽  
Chromosomal Microarray ◽  
Mek Inhibition ◽  
Follow Up Study ◽  
The Family ◽  
The Relationship

Abstract PURPOSE To describe decreased growth velocity with long term use of BRAFV600e and MEK inhibition in a patient with anaplastic ganglioglioma. RESULTS 4-year-old patient was found to have a 6 x 4.6 x 5 cm mass in the hypothalamus. Pathology consistent with anaplastic ganglioglioma and chromosomal microarray revealed a BRAFV600e mutation. Patient started on dabrafenib and trametinib and tumor decreased 85% after 3 months. She is stable without significant toxicities 39 months on therapy, and is now 8 years old. Patient had been growing at the 25% for weight and 12% for height but is now 65% for weight and 0.5% for height. It is difficult to tease out the relationship between the tumor, the location of the tumor, and the BRAF and MEK inhibitors and their effect on growth. Discussions with the family and endocrinology are ongoing but being <1% for height will lead to decrease in quality of life. CONCLUSIONS Further follow-up study is needed to determine if this is truly a long-term toxicity, or if this may just be a direct result of the location of the tumor. Would supplementation with growth hormone in this patient lead to losing control of a high grade tumor, or would it simply replace a hormone that is not produced?

scholarly journals Quality of life of elderly with alzheimer’s disease: a comparative study between the patient’s and the caregiver’s report

2010 ◽  
Vol 18 (1) ◽  
pp. 26-32 ◽  
Author(s):  
Keika Inouye ◽  
Elisete Silva Pedrazzani ◽  
Sofia Cristina Iost Pavarini ◽  
Cristina Yoshie Toyoda
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Life Assessment ◽  
Quality Of Life Assessment ◽  
Patient Reports ◽  
The Family ◽  
Final Score ◽  
High Level

This paper aimed to compare the reports of patients and caregivers about how they perceive quality of life (QoL) in general and each of its dimensions in elderly with Alzheimer’s Disease (AD). The participants were elderly diagnosed with AD (n=53) attended by the Exceptional Medication Program in a city in the interior of Sao Paulo; and their respective family caregivers. The QoL measures were obtained through the Quality of Life Assessment Scale on Alzheimer’s Disease. The results showed statistically significant differences in the “memory” (p<0.05) and “you in general” (p<0.005) dimensions. Regarding the final score, the average in the patient’s version was 29.32 points (sd=6.27), against 28.33 points (sd=5.58) in the family version, p>0.100. Although the relative and patient reports were not identical, the results pointed to a high level of consistency among information.

Abstract 1829: Predictors of quality of life among Hispanic and non-Hispanic White women: A 15 year follow-up study of long-term breast cancer survivors

2011 ◽  
Author(s):  
Stephanie R. Denkhoff ◽  
Dongyan Yang ◽  
Christina M. Pinkston ◽  
Richard N. Baumgartner ◽  
Kathy B. Baumgartner
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
White Women ◽  
Follow Up Study ◽  
Hispanic White

Long-term outcomes of an integrative rehabilitation program on quality of life: A follow-up study

2006 ◽  
Vol 61 (6) ◽  
pp. 835-839 ◽  
Author(s):  
Renee R. Taylor ◽  
Sachi G. Thanawala ◽  
Yukiko Shiraishi ◽  
Michael E. Schoeny
Keyword(s):  
Quality Of Life ◽  
Rehabilitation Program ◽  
Long Term Outcomes ◽  
Follow Up Study

Proxy-rated quality of life in Alzheimer's disease: a three-year longitudinal study

2011 ◽  
Vol 24 (1) ◽  
pp. 82-89 ◽  
Author(s):  
Asmus Vogel ◽  
Suvosree Bhattacharya ◽  
Frans B. Waldorff ◽  
Gunhild Waldemar
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Primary Caregivers ◽  
Individual Variations ◽  
Home Living ◽  
State Examination ◽  
Eq Vas

ABSTRACTBackground: The study investigated the change in proxy rated quality of life (QoL) of a large cohort of home living patients with Alzheimer's disease (AD) over a period of 36 months.Methods: The sample consisted of 102 patients with mild AD and their primary caregivers from the Danish Alzheimer's Disease Intervention Study. QoL was assessed with the proxy-rated (primary caregivers) Quality of Life in Alzheimer Disease scale (QOL-AD) and the EuroQuol Visual Analogue Scale (EQ-VAS) scale. The Cornell Scale for Depression in Dementia (CSDD), Alzheimer's Disease Cooperative Study, Activities of Daily living Inventory (ADCS-ADL), Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory (NPI-Q) were also applied. Evaluations were conducted at baseline and at 12 and 36 months follow-up.Results: There was a significant decline in mean QoL assessed by both the QOL-AD and the EQ-VAS (p < 0.001). There were vast individual differences in the QoL scores on both scales at 12 and 36 months’ follow-up. Mean change from baseline in QOL-AD was significantly associated with change in CSDD, ADCS-ADL and MMSE scores at 12 months and with ADCS-ADL score at 36 months.Conclusion: QoL is a subjective concept and may not be influenced by the degree of cognitive dysfunction. Future studies should investigate the factors for individual variations in order to understand the nature of change of QoL in AD and the wide variation in QoL scores over time.

scholarly journals Quality of life and functionality after total hip arthroplasty: a long-term follow-up study

2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Massimo Mariconda ◽  
Olimpio Galasso ◽  
Giovan Giuseppe Costa ◽  
Pasquale Recano ◽  
Simone Cerbasi
Keyword(s):  
Quality Of Life ◽  
Total Hip Arthroplasty ◽  
Hip Arthroplasty ◽  
Total Hip ◽  
Follow Up Study ◽  
Long Term Follow Up

Quality of Life: The Family and Alzheimer's Disease

1992 ◽  
Vol 8 (3) ◽  
pp. 56-60 ◽  
Author(s):  
Mary Guerrero Austrom ◽  
Hugh C. Hendrie
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Family

scholarly journals Quality of life after bone sarcoma surgery around the knee: A long-term follow-up study

2016 ◽  
Vol 26 (4) ◽  
pp. e12603 ◽  
Author(s):  
W.P. Bekkering ◽  
J.C. van Egmond-van Dam ◽  
J.A.M. Bramer ◽  
A. Beishuizen ◽  
M. Fiocco ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bone Sarcoma ◽  
Follow Up Study ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document